Across TCGA pan-cancer cohorts, HERC2P9 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated HERC2P9 data layer compared with 23 for mass-spec protein.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher HERC2P9 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HERC2P9 expression acts as an unfavorable survival marker.
LIHC, HNSC, and PRAD are the cancer types where HERC2P9 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.